Literature DB >> 30393191

Exploring the association between SRPX2 variants and neurodevelopment: How causal is it?

Schaida Schirwani1, Vivienne McConnell2, Josh Willoughby3, Meena Balasubramanian4.   

Abstract

The SRPX2 gene (Sushi-repeat-containing protein, X-linked, 2, OMIM*300642), located on Xq22.1, encodes a secreted protein that is highly expressed in neurons of cerebral cortex. SRPX2 was first implicated in neurodevelopment, learning and rolandic seizure when two patients with potentially pathogenic variants, c.980A>G (p.Asn327Ser) and c.215A>C (p.Tyr72Ser), in SRPX2 gene were identified. Subsequent experimental studies demonstrated that SRPX2 is needed for vocalization and synapse formation in mice, and that both silencing SRPX2 and injecting (p.Asn327Ser) in mouse models results in alteration in neuronal migration in cerebral cortex and epilepsy. A number of studies demonstrated that SRPX2 interacts with FOXP2 (Foxhead box protein P2), a gene responsible for speech and language disorder, and that FoxP2 controls timing and level of expression of SRPX2. Despite the supportive evidence for the role of SRPX2 in speech and language development and disorders, there are questions over its definitive association with neurodevelopmental disorders and epilepsy. In this paper, the role of SRPX2 as one in a network of many genes involved in speech and language is discussed. The goal of this paper is to examine the role of SRPX2 variants through describing two patients with potentially pathogenic variants in SRPX2, c.751G>C (p.Ala251Pro) and c.762G>T (p.Lys254Asn) presenting with language and motor delay, intellectual disability as well as congenital anomalies. We explore the contribution of SRPX2 variants to clinical phenotype in our patients and conclude that these variants at least partially explain the phenotype. Further studies are necessary to establish and confirm the association between SRPX2 and neurodevelopment particularly speech and language development.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FOXP2; Neurodevelopmental delay; Rolandic epilepsy; SRPX2; Seizures; Speech and language impairment

Mesh:

Substances:

Year:  2018        PMID: 30393191     DOI: 10.1016/j.gene.2018.10.067

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  4 in total

Review 1.  Complement and microglia dependent synapse elimination in brain development.

Authors:  Breeanne M Soteros; Gek Ming Sia
Journal:  WIREs Mech Dis       Date:  2021-11-04

2.  The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development.

Authors:  Qifei Cong; Breeanne M Soteros; Mackenna Wollet; Jun Hee Kim; Gek-Ming Sia
Journal:  Nat Neurosci       Date:  2020-07-13       Impact factor: 24.884

3.  Proteomic analysis of bone marrow-derived mesenchymal stem cell extracellular vesicles from healthy donors: implications for proliferation, angiogenesis, Wnt signaling, and the basement membrane.

Authors:  Jeffrey D McBride; Luis Rodriguez-Menocal; Wellington Guzman; Aisha Khan; Ciara Myer; Xiaochen Liu; Sanjoy K Bhattacharya; Evangelos V Badiavas
Journal:  Stem Cell Res Ther       Date:  2021-06-05       Impact factor: 6.832

4.  Activated Mesenchymal Stem Cells Induce Recovery Following Stroke Via Regulation of Inflammation and Oligodendrogenesis.

Authors:  Matthew K Tobin; Terilyn K L Stephen; Kyra L Lopez; Melissa R Pergande; Amelia M Bartholomew; Stephanie M Cologna; Orly Lazarov
Journal:  J Am Heart Assoc       Date:  2020-03-24       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.